Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase NA 1Phase 3 1Phase 2/3 1

Status

Completed 9Recruiting 2Not yet recruiting 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9toripalimab 8venetoclax 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7Carboplatin 7pembrolizumab 6irinotecan sucrosofate 6Temozolomide 6HMPL-013 6tislelizumab 5sintilimab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Fluorouracil 5Etoposide 5Cisplatin 5Biopsy 5osimertinib 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Prednisolone × Clear all
NCT07387926 2026-05-19

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Novartis

Phase 1/2 Not yet recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07035379 2025-08-22

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL

Zhejiang Teruisi Pharmaceutical Inc.

Phase 1/2 Not yet recruiting
66 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡